Up-Front Chemoradiotherapy Plus Consolidation Chemotherapy Yields High pCR Rate in Advanced Rectal Cancer

Article

Patients with advanced rectal cancer who were treated with up-front chemoradiotherapy plus consolidation chemotherapy experienced an improvement in pathological complete response without impacting disease-free survival.

Up-front chemoradiotherapy (CRT) plus consolidation chemotherapy yielded a higher rate of pathological complete response (pCR) among patients with advanced rectal cancer without negatively impacting disease-free survival (DFS), toxicity, quality of life, or stool incontinence, according to long-term findings from the phase 2 CAO/ARO/AIO-12 trial (NCT02363374) published in JAMA Oncology.

In both groups, with group A receiving fluorouracil, leucovorin, and oxaliplatin prior to CRT and group B receiving CRT prior to chemotherapy, the 3-year DFS was 73% (95% CI, 66%-80%; HR, 0.95; 95% CI, 0.63-1.45; P = .82). Investigators did not report a significant difference in locoregional recurrence between group A (6%; 95% CI, 2%-10%) and group B (5%; 95% CI, 1%-9%; HR, 0.81; 95% CI, 0.30-2.18;P = .67). Additionally, distant metastases were similar between the 2 arms (Group A: 18%; 95% CI, 12%-24%; Group B: 16%; 95% CI, 9%-22%; P = .52).

“We suggest that up-front CRT followed by consolidation chemotherapy may be the preferred total neoadjuvant therapy sequence if organ preservation is a priority. This sequence resulted in higher rates of pCR without compromising DFS, toxicity, or quality of life,” investigators of the study wrote.

A total of 311 patients enrolled on the study, 306 of whom were evaluable. A total of 156 patients were randomized to group A and 150 were randomized to group B. In group A, all patients started treatment with induction chemotherapy, with 97% undergoing CRT and 92% receiving surgery. In group B, 99% of patients began treatment with CRT, with 93% receiving consolidation chemotherapy and 95% undergoing surgery.

The study had a median follow-up time of 43 months. Across both groups, 2 patients had treatment-related deaths, 14 had deaths related to their disease, 1 death was due to second primary tumor, and 12 were due to other causes. In groups A and B, the overall survival was 92% (95% CI, 88%-97%; HR, 1.10; 95% CI, 0.53-2.27; P = .81).

Four percent of patients in group A and 3% in group B had a clinical CR and did not agree to undergo surgery. However, 3 months later in group A, 1 patient had developed endoluminal tumor growth and underwent abdominoperineal resection; the patient was disease-free through follow-up. At 27 months in group B, 1 patient experiencesd local regrowth and distant metastases of the liver and lung after total neoadjuvant therapy and received palliative chemotherapy. 

At 12 months, the rates of chronic toxicity of grades 3/4 were 15.4% in group A and 17.4% in group B. At 36 months, the rates were 11.8% and 9.9% in groups A and B, respectively. Grade 3/4 oxaliplatin-induced neurotoxicity occurred in 9.4% of patients in group A and 9.2% of those in group B at 12 months. At 36 months, the rates were 1.2% in group A and 2.5% in group B.

A total of 89% of patients completed the patient reported outcome measures at baseline, 69% of which were completed prior to surgery, 58% were completed at treatment conclusion, 61% were completed at 12 months, 54% were completed at 24 months, and 41% were completed at 36 months. Investigators reported that there were no differences seen in response rates or missing items between either group. Additionally, a difference in quality-of-life score was not seen between the 2 groups.

Other findings indicated that patients did not have a difference in stool incontinence. Scores were worse at 12 months, and only improved slightly at 24 and 36 months. However, scores never reached baseline levels. In 11.3% of patients vs 9.6% of patients in groups A and B, respectively, at 12 months normal stool continence was observed. Moreover, 34% vs 36.5% had minor stool incontinence, 32.1% vs 25% had average stool incontinence, and 22.6% vs 28.8% had complete stool incontinence in groups A and B, respectively.

Reference

Fokas E, Schlenska-Lange A, Polat B, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2021;e215445. doi:10.1001/jamaoncol.2021.5445

 

Related Videos
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Aparna Parikh, MD, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Related Content